Why Early-Stage SaaS Needs an Executable Market Before It Needs More Pipeline
There is a slide in almost every SaaS pitch deck that makes me nervous.
TAM: £10bn.
Then comes the seemingly reasonable conclusion:
If we capture just 1%...
The maths is usually impeccable.
The GTM logic often isn't.
Because your Total Addressable Market is not your sales market.
It tells investors how big the opportunity could eventually become. It does not tell your sales team who they should be trying to sell to on Monday morning.
And confusing the two is one of the fastest ways to make an emerging sales motion look broken.
TAM answers the wrong question
TAM asks:
Who could theoretically buy this product?
That's an important question when you're assessing the size of an opportunity.
But it's a terrible way to build a sales territory.
Your sales team needs the answer to a very different question:
Who can we credibly win right now?
Not everyone who has the problem.
Not everyone who could use the product.
Not every company in the industries listed on your website.
The companies where your current product, message, proof, pricing and sales motion give you a genuine right to win.
That's your Executable Market.
And it's usually much smaller than your TAM.
It should be.
The problem with "we can sell to anyone"
I've heard some version of this countless times:
"Our product is horizontal. We can sell to pretty much any company with more than 500 employees."
That sounds like opportunity.
To a salesperson, it often means chaos.
Because if you can sell to everyone, you haven't told the sales team where to focus.
One AE goes after financial services.
Another finds a manufacturing opportunity.
An SDR gets traction in professional services.
The founder closes a technology company through their network.
Marketing generates leads from somewhere else entirely.
Revenue may still happen.
But you're learning almost nothing.
Every deal has a different context.
Different pain.
Different buyer.
Different message.
Different objections.
Different proof requirements.
Potentially a different sales process.
Then six months later someone looks at conversion rates and concludes:
"The sales team isn't performing."
Maybe.
Or perhaps you've asked them to execute across five different markets simultaneously.
Focus creates repeatability
This connects directly to the argument I've been making about Minimum Viable Repeatability.
You cannot determine whether a sales motion is repeatable if you keep changing the environment in which you're testing it.
Imagine trying to test a scientific hypothesis while changing three variables every time you run the experiment.
That's effectively what happens when an early sales team is allowed to chase anything that moves.
One deal is a 200-person SaaS company.
The next is a 10,000-person bank.
The next comes through a partner.
The next is founder-referred.
The next is an inbound lead from an industry you've never sold into before.
Then we aggregate all of those opportunities into a CRM dashboard and try to calculate a conversion rate.
What exactly are we measuring?
Repeatability requires controlled learning.
And controlled learning requires focus.
Your Executable Market
I think early-stage businesses need another layer between ICP and TAM.
I call it the Executable Market.
Your TAM might contain 50,000 companies.
Your ICP might narrow that to 8,000.
But perhaps there are only 600 accounts where, today:
Those 600 companies are far more valuable to your sales team than a spreadsheet containing 8,000 theoretically suitable accounts.
Because they're executable.
This isn't about making the opportunity smaller
This is usually where the resistance appears.
"But we don't want to limit the market."
You aren't.
You're sequencing it.
There is a huge difference.
Your Executable Market is not a declaration that you will never sell anywhere else.
It's a decision about where you have the highest probability of winning now.
Win there.
Build proof.
Learn the language.
Understand the objections.
Create references.
Improve the product.
Make the motion repeatable.
Then expand the boundary.
Your Executable Market should grow as your capability grows.
What you can credibly attack at £1m ARR should look very different from what you can attack at £10m ARR.
That's not a weakness.
That's GTM maturity.
The founder can hide this problem
Founder-led sales makes this particularly dangerous.
A good founder can often sell outside the company's natural Executable Market.
They can carry gaps in the product.
They can change the pitch halfway through the meeting.
They can bring extraordinary credibility to the conversation.
They can negotiate commercially in real time.
They can promise where the product is going.
And they can use relationships that nobody else in the business possesses.
Then the company hires its first salespeople and hands them a list of "similar" accounts.
But those accounts aren't necessarily similar at all.
They were simply companies the founder managed to close.
Founder capability has been mistaken for market validation.
We've seen this problem before.
Revenue proves somebody will buy.
It doesn't necessarily prove somebody else can sell.
And a TAM proves somebody could buy.
It certainly doesn't prove you know how to win them.
Pipeline can make the problem worse
When growth slows, the instinctive response is often:
We need more pipeline.
So marketing increases spend.
SDRs increase activity.
More accounts enter sequences.
More industries get targeted.
More opportunities appear in CRM.
The top of the funnel gets bigger.
But if the market underneath it hasn't been properly defined, you've simply increased the volume of the experiment.
More pipeline doesn't fix weak market selection.
It amplifies it.
This is why I think one of the most dangerous questions in early-stage SaaS is:
"How do we generate more pipeline?"
asked before:
"Where have we actually earned the right to sell?"
Make the market earn its way into the sales plan
Before adding another segment, vertical or account type to the sales motion, I'd want evidence.
Have we won there before?
Do we understand why?
Does the same problem consistently appear?
Can we identify the buyer?
Does our message travel?
Can someone other than the founder create and progress the opportunity?
Can we win at an ACV and sales cycle that makes economic sense?
If the answer is repeatedly yes, expand the Executable Market.
If it isn't, putting those accounts into Salesforce doesn't make them a market.
It makes them a hypothesis.
And hypotheses should be tested deliberately, not quietly turned into somebody's quota.
TAM is about possibility. Execution is about probability.
This is ultimately the distinction.
A large TAM matters.
You need somewhere to grow.
But early-stage GTM isn't a land grab.
It's a learning system.
The objective isn't to prove that lots of companies could buy your product.
It's to identify a group of companies where you understand why they buy, how they buy and how you can repeatedly win them.
Then do it again.
And again.
And again.
Until that market becomes predictable enough that you can widen the aperture.
TAM tells you how big the opportunity might become.
Your Executable Market tells you where you have earned the right to compete today.
Don't hand your sales team the first one and expect them to discover the second.
Written by Paul Wingfield.
View the original on LinkedIn ↗